Origami Therapeutics develops therapies targeting and degrading disease-related proteins to treat neurodegenerative diseases like Alzheimer's, Huntington's, and Parkinson's.
Founded
2015
Revenue
$1-5M
Company Stage
Seed
YC Batch
W22
Product Features & Capabilities
disease-modifying protein degraders, therapies targeting and degrading disease-related proteins, selective and efficient degradation of disease-causing proteins, small molecules for broad distribution and ease of manufacture, focus on neurodegenerative diseases including Alzheimer's, Huntington's, P
